As Platform Specialty Prods Cor (PAH) Stock Value Rose, Shareholder Kamunting Street Capital Management LP Decreased Its Position by $350,086; Immunomedics (IMMU) Market Value Declined While Ghost Tree Capital Has Trimmed by $13.80 Million Its Holding

September 14, 2018 - By Clara Lewis

Immunomedics, Inc. (NASDAQ:IMMU) Logo

Ghost Tree Capital Llc decreased its stake in Immunomedics Inc (IMMU) by 32.43% based on its latest 2018Q2 regulatory filing with the SEC. Ghost Tree Capital Llc sold 600,000 shares as the company’s stock declined 0.90% while stock markets rallied. The hedge fund held 1.25M shares of the health care company at the end of 2018Q2, valued at $29.59M, down from 1.85M at the end of the previous reported quarter. Ghost Tree Capital Llc who had been investing in Immunomedics Inc for a number of months, seems to be less bullish one the $4.16B market cap company. The stock decreased 1.64% or $0.37 during the last trading session, reaching $22.24. About 963,904 shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 107.13% since September 14, 2017 and is uptrending. It has outperformed by 91.51% the S&P500. Some Historical IMMU News: 09/05/2018 – IMMUNOMEDICS 3Q LOSS/SHR 21C, EST. LOSS/SHR 15C; 21/05/2018 – Biotech Analysis Central Preview Series: ImmunoMedics; 09/05/2018 – Immunomedics 3Q Loss $35.5M; 12/04/2018 – Immunomedics Closes Above 50-Day Moving Average: Technicals; 09/04/2018 lmmunomedics Appoints Dr. Robert lannone Head of Research & Development and Chief Medical Officer; 21/05/2018 – Immunomedics Submits Biologics License Application for Sacituzumab Govitecan to the U.S. FDA; 21/05/2018 – lmmunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration; 19/04/2018 – DJ Immunomedics Inc, Inst Holders, 1Q 2018 (IMMU); 21/05/2018 – IMMUNOMEDICS SUBMITS BLA FOR SACITUZUMAB GOVITECAN TO U.S. FDA; 21/05/2018 – IMMUNOMEDICS INC – FILING IS BASED ON PHASE 1/2 DATA OF SACITUZUMAB GOVITECAN IN MTNBC

Kamunting Street Capital Management Lp decreased its stake in Platform Specialty Prods Cor (PAH) by 12.26% based on its latest 2018Q2 regulatory filing with the SEC. Kamunting Street Capital Management Lp sold 31,826 shares as the company’s stock rose 5.68% with the market. The hedge fund held 227,859 shares of the major chemicals company at the end of 2018Q2, valued at $2.64M, down from 259,685 at the end of the previous reported quarter. Kamunting Street Capital Management Lp who had been investing in Platform Specialty Prods Cor for a number of months, seems to be less bullish one the $3.71 billion market cap company. The stock increased 0.98% or $0.125 during the last trading session, reaching $12.875. About 526,285 shares traded. Platform Specialty Products Corporation (NYSE:PAH) has risen 6.83% since September 14, 2017 and is uptrending. It has underperformed by 8.79% the S&P500. Some Historical PAH News: 09/05/2018 – Platform Specialty Products Corporation Announces the Closing of its Acquisition of HiTech Korea Co., Ltd by MacDermid Performa; 03/05/2018 – Platform Specialty 1Q Adj EPS 21c; 03/05/2018 – Platform Specialty 1Q Net $37.3M; 03/05/2018 – MARTIN E. FRANKLIN – HAD PREVIOSULY REPORTED 5.1 PCT STAKE IN PLATFORM SPECIALTY PRODUCTS CORP AS OF DECEMBER 18, 2017 – SEC FILING; 03/05/2018 – Platform Specialty 1Q EPS 13c; 10/05/2018 – Platform Specialty at Goldman Sachs Conference May 16; 03/05/2018 – PLATFORM SPECIALTY PRODUCTS CORP – REAFFIRMING FULL YEAR 2018 ADJUSTED EBITDA GUIDANCE OF $870 MLN TO $900 MLN; 20/03/2018 Platform Specialty Access Event Set By SunTrust for Mar. 27; 03/05/2018 – PLATFORM SPECIALTY 1Q ADJ EBITDA $207M, EST. $196.0M; 24/04/2018 – Platform Specialty Closes Below 50-Day Moving Average

Investors sentiment increased to 1.04 in Q2 2018. Its up 0.04, from 1 in 2018Q1. It is positive, as 23 investors sold PAH shares while 55 reduced holdings. 32 funds opened positions while 49 raised stakes. 247.72 million shares or 3.13% less from 255.74 million shares in 2018Q1 were reported. Tcw Grp Inc has invested 0% of its portfolio in Platform Specialty Products Corporation (NYSE:PAH). 3,854 are owned by Lorber David A. Guggenheim Capital Lc holds 0% in Platform Specialty Products Corporation (NYSE:PAH) or 33,272 shares. 19,700 were accumulated by Renaissance Technology Ltd Llc. Scopus Asset Mgmt LP has 0.05% invested in Platform Specialty Products Corporation (NYSE:PAH) for 450,000 shares. Tokio Marine Asset, a Japan-based fund reported 47,800 shares. Ing Groep Nv stated it has 88,800 shares or 0.02% of all its holdings. Victory Cap Management Incorporated stated it has 0.09% of its portfolio in Platform Specialty Products Corporation (NYSE:PAH). National Bank Of Montreal Can holds 1.18M shares. Raymond James & Assocs reported 0.01% of its portfolio in Platform Specialty Products Corporation (NYSE:PAH). Blackrock Incorporated reported 15.18 million shares or 0.01% of all its holdings. Geode Cap Management Ltd Co owns 1.89 million shares for 0.01% of their portfolio. Ancora Advsr Ltd Liability Com holds 1.67 million shares. Cubist Systematic Strategies Limited Liability holds 39,513 shares. First Manhattan Communications holds 0.16% of its portfolio in Platform Specialty Products Corporation (NYSE:PAH) for 2.33 million shares.

Since August 13, 2018, it had 4 buys, and 0 insider sales for $4.05 million activity. Shares for $251,038 were bought by Capps John Edward. $3.12 million worth of stock was bought by FRANKLIN MARTIN E on Monday, August 13. Benson Scot also bought $75,360 worth of Platform Specialty Products Corporation (NYSE:PAH) shares.

Analysts await Platform Specialty Products Corporation (NYSE:PAH) to report earnings on November, 1. They expect $0.07 EPS, down 58.82% or $0.10 from last year’s $0.17 per share. PAH’s profit will be $20.18M for 45.98 P/E if the $0.07 EPS becomes a reality. After $0.26 actual EPS reported by Platform Specialty Products Corporation for the previous quarter, Wall Street now forecasts -73.08% negative EPS growth.

Among 10 analysts covering Platform Specialty Products Corporation (NYSE:PAH), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. Platform Specialty Products Corporation had 27 analyst reports since August 17, 2015 according to SRatingsIntel. The rating was reinitiated by Credit Suisse on Thursday, December 3 with “Neutral”. The stock of Platform Specialty Products Corporation (NYSE:PAH) earned “Neutral” rating by Credit Suisse on Monday, May 2. The rating was maintained by Barclays Capital with “Equal Weight” on Wednesday, October 5. The stock of Platform Specialty Products Corporation (NYSE:PAH) earned “Buy” rating by SunTrust on Monday, September 18. On Monday, August 22 the stock rating was initiated by TH Capital with “Buy”. Credit Suisse maintained it with “Neutral” rating and $12 target in Wednesday, November 15 report. SunTrust maintained the stock with “Buy” rating in Thursday, November 2 report. The rating was upgraded by Nomura on Monday, November 7 to “Buy”. The firm has “Equal-Weight” rating by Barclays Capital given on Tuesday, August 16. The stock has “Buy” rating by Roth Capital on Monday, August 22.

Ghost Tree Capital Llc, which manages about $339.79M US Long portfolio, upped its stake in Anaptysbio Inc by 6,700 shares to 15,700 shares, valued at $1.12M in 2018Q2, according to the filing. It also increased its holding in Ascendis Pharma A S by 35,000 shares in the quarter, for a total of 175,000 shares, and has risen its stake in Acadia Pharmaceuticals Inc (NASDAQ:ACAD).

Since June 15, 2018, it had 2 insider purchases, and 0 selling transactions for $18.48 million activity.

More notable recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: Globenewswire.com which released: “Immunomedics and Samsung BioLogics Announce Strategic Manufacturing Partnership” on September 12, 2018, also Streetinsider.com with their article: “Immunomedics (IMMU), Samsung BioLogics Announce Strategic Manufacturing Partnership” published on September 13, 2018, Seekingalpha.com published: “Immunomedics: Why This Biotech Could Go Crazy In 2019” on August 29, 2018. More interesting news about Immunomedics, Inc. (NASDAQ:IMMU) were released by: Seekingalpha.com and their article: “Immunomedics CFO resigns position, stays on as VP Finance” published on August 23, 2018 as well as Nasdaq.com‘s news article titled: “Immunomedics is Now Oversold (IMMU)” with publication date: August 17, 2018.

Among 4 analysts covering Immunomedics (NASDAQ:IMMU), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immunomedics had 19 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, October 9 by Jefferies. As per Thursday, August 17, the company rating was maintained by Jefferies. The firm earned “Buy” rating on Friday, August 24 by FBR Capital. The firm has “Buy” rating given on Thursday, May 17 by Wells Fargo. The stock has “Market Perform” rating by Wells Fargo on Tuesday, June 21. Jefferies downgraded it to “Hold” rating and $2 target in Wednesday, July 29 report. On Friday, December 4 the stock rating was downgraded by Wells Fargo to “Market Perform”. Cowen & Co maintained the shares of IMMU in report on Monday, July 24 with “Buy” rating. The stock of Immunomedics, Inc. (NASDAQ:IMMU) earned “Buy” rating by Wells Fargo on Monday, June 4. The rating was maintained by Jefferies with “Buy” on Friday, June 9.

Investors sentiment increased to 1.86 in Q2 2018. Its up 0.60, from 1.26 in 2018Q1. It improved, as 20 investors sold IMMU shares while 38 reduced holdings. 43 funds opened positions while 65 raised stakes. 139.30 million shares or 18.50% more from 117.56 million shares in 2018Q1 were reported. Fmr Ltd Liability Corp invested in 8.49M shares or 0.02% of the stock. Bluecrest Capital Mngmt Ltd accumulated 19,400 shares. Sg Americas Secs Ltd Liability Corp invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Voloridge Invest Mngmt Limited Liability Company has invested 0.08% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Shaker Invests Ltd Llc Oh invested 1.23% in Immunomedics, Inc. (NASDAQ:IMMU). Tiaa Cref Invest Mgmt Ltd Co reported 289,743 shares. Vanguard Grp Inc Inc reported 14.17 million shares. Public Employees Retirement Association Of Colorado, Colorado-based fund reported 21,350 shares. Adage Capital Prtn Limited invested in 150,000 shares. Panagora Asset Mngmt Incorporated has invested 0.06% in Immunomedics, Inc. (NASDAQ:IMMU). D E Shaw And reported 0% in Immunomedics, Inc. (NASDAQ:IMMU). Knott David M stated it has 0.28% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Dafna Mgmt Ltd Liability Co has 2.03% invested in Immunomedics, Inc. (NASDAQ:IMMU). Gotham Asset Management Ltd holds 23,881 shares or 0.01% of its portfolio. Strs Ohio owns 64,551 shares.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on November, 8. They expect $-0.26 EPS, down 62.50% or $0.10 from last year’s $-0.16 per share. After $-0.34 actual EPS reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts -23.53% EPS growth.

Platform Specialty Products Corporation (NYSE:PAH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts